Home Daily Intelligence Tracker
    • Plans Blog Contact
    Arrowhead Pharmaceuticals Inc logo
    ARWR

    Arrowhead Pharmaceuticals Inc

    MaveScore 18 Low model confidence
    Last Price US$74.61 As of Jul 14, 2026
    DCF Fair Price US$16.64 Research estimate · Jul 14, 2026 -77.6% vs price
    Market Cap US$10.7b Company size context
    7D Performance -14.19% Past 7 days
    1Y Performance 300.73% Past 12 months
    Model Rating
    Historical model output for research review

    Industry and sector peers, plus broader research alternatives

    View comparison
    Halozyme Therapeutics Inc HALO Industry peer Corcept Therapeutics Incorporated CORT Industry peer Exelixis Inc EXEL Industry peer Zoetis Inc ZTS Sector peer

    Fundamental data date

    Mar 31, 2026

    105 days old

    Market price date

    Jul 14, 2026

    1 day old

    Coverage

    16/16

    No missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Loading Mave Thesis research outlook

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 18 Low confidence

    Stored data quality

    Freshness and coverage checks

    16/16 Current stored snapshot

    Quality

    3/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    7/25 Weak

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    0/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    8/15 Mixed

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    0/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Rewards durable profitability, margins, and positive free cash flow.
    • Favors positive earnings, positive cash flow, and lower multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Arrowhead Pharmaceuticals Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated wi Read More

    Arrowhead Pharmaceuticals Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Arrowhead Pharmaceuticals Inc

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 07, 2026

    Quarterly result summary

    Revenue was $73.7M (-86% YoY).

    Revenue $73.7M -86% YoY

    What changed

    • Revenue -86% YoY to $73.7M.

    Guidance / outlook

    the company anticipates it will be marketed independently by Arrowhead; • Presented new long-term efficacy and safety data for plozasiran across a spectrum of hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 8-K May 07, 2026 SEC filing 10-Q May 07, 2026 Earnings release Earnings release Feb 05, 2026 SEC filing 10-Q Feb 05, 2026 SEC filing 8-K Feb 05, 2026 Earnings release Earnings release Nov 25, 2025 SEC filing 8-K Nov 25, 2025 SEC filing 10-K Nov 25, 2025 SEC filing 10-K/A Oct 10, 2025 SEC filing 8-K Aug 07, 2025 Earnings release Earnings release Aug 07, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 0.00/5
    Arrowhead Pharmaceuticals Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 0.53/5
    Arrowhead Pharmaceuticals Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Arrowhead Ph... ARWR US$10.7b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 0.57/5
    Arrowhead Pharmaceuticals Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Arrowhead Ph... ARWR US$10.7b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 2.34/5
    Arrowhead Pharmaceuticals Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Arrowhead Ph... ARWR US$10.7b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Arrowhead Pharmaceuticals Inc logo

    Arrowhead Pharmaceuticals Inc

    US$74.61

    US$16.64

    -77.6% vs price

    US$10.7b

    -14.19%

    300.73%